Literature DB >> 3130348

Effect of culture supernatant of MT-2 cells on human immunodeficiency virus-producing cells, MOLT-4/HIVHTLV-IIIB cells.

T Matsuyama1, Y Hamamoto, T Yoshida, Y Kido, S Kobayashi, N Kobayashi, N Yamamoto.   

Abstract

The effect of culture supernatant of MT-2 cells on human immunodeficiency virus (HIV)-producing cells, MOLT-4/HIVHTLV-IIIB cells, was examined. As compared to the effect on MOLT-4 cells, parent cells not infected with HIV, a selective cytotoxic/cytostatic effect on MOLT-4/HIVHTLV-IIIB cells was observed 4 days after treatment with up to 640-fold-diluted MT-2 supernatant. Furthermore, under similar conditions, a 2- to 6-fold increase in the number of HIV particles was detected in the culture of MOLT-4/HIVHTLV-IIIB cells 6 hr after treatment. Complete blocking of these effects by anti-lymphotoxin monoclonal antibody, but not by anti-tumor necrosis factor antibody, indicates that these effects of MT-2 supernatant on MOLT-4/HIVHTLV-IIIB cells are attributable to a lymphotoxin-related cytotoxic factor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130348      PMCID: PMC5917466          DOI: 10.1111/j.1349-7006.1988.tb01571.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  10 in total

1.  Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4.

Authors:  R Kikukawa; Y Koyanagi; S Harada; N Kobayashi; M Hatanaka; N Yamamoto
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

5.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

6.  Recombinant human tumor necrosis factor--I. Cytotoxic activity in vitro.

Authors:  K Nakano; S Abe; Y Sohmura
Journal:  Int J Immunopharmacol       Date:  1986

7.  Tumor promoter, TPA, enhances replication of HTLV-III/LAV.

Authors:  S Harada; Y Koyanagi; H Nakashima; N Kobayashi; N Yamamoto
Journal:  Virology       Date:  1986-10-30       Impact factor: 3.616

8.  Production of cytotoxic factor(s) in human T cell lines transformed by a human retrovirus.

Authors:  S Hinuma; K Naruo; K Tsukamoto; K Sugamura; Y Hinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-08-15       Impact factor: 3.575

9.  Selective cytotoxicity of AIDS virus infection towards HTLV-I-transformed cell lines.

Authors:  Y Koyanagi; S Harada; M Takahashi; F Uchino; N Yamamoto
Journal:  Int J Cancer       Date:  1985-10-15       Impact factor: 7.396

10.  Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons.

Authors:  G H Wong; D V Goeddel
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

  10 in total
  9 in total

Review 1.  Is TNF involved in the progression of AIDS?

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto
Journal:  Virus Genes       Date:  1990-07       Impact factor: 2.332

2.  Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication.

Authors:  T Matsuyama; Y Hamamoto; G Soma; D Mizuno; N Yamamoto; N Kobayashi
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication.

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto; A Ishii; M Yonehara; S Yonehara
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Enhancement of human immunodeficiency virus production by natural lymphotoxin.

Authors:  T Matsuyama; Y Hamamoto; S Kobayashi; M Kurimoto; J Minowada; N Kobayashi; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

5.  Production of tumor necrosis factors by human T cell lines infected with HTLV-1 may cause their high susceptibility to human immunodeficiency virus infection.

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

6.  Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1.

Authors:  E Fenouillet; J C Gluckman; E Bahraoui
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

7.  Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.

Authors:  Tetsuya Adachi; Reiko Tanaka; Akira Kodama; Mineki Saito; Yoshiaki Takahashi; Aftab A Ansari; Yuetsu Tanaka
Journal:  Retrovirology       Date:  2011-10-22       Impact factor: 4.602

8.  "How many times did I not want to live a life because of him": the complex connections between child sexual abuse, disclosure, and self-injurious thoughts and behaviors.

Authors:  Delphine Collin-Vézina; Mireille De La Sablonnière-Griffin; Marudan Sivagurunathan; Rusan Lateef; Ramona Alaggia; Rosaleen McElvaney; Megan Simpson
Journal:  Borderline Personal Disord Emot Dysregul       Date:  2021-01-04

9.  Synergistic effect of chronic pain and nonsuicidal self-harm on pain sensitivity.

Authors:  Diane J Kim; Asha Job; Srinivasa Gokarakonda; Chuan Huang; Lackshminarayana Chekuri; Jessica M Carbajal; Ricardo Cáceda
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-06-21       Impact factor: 5.270

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.